DR. BARRY J BYRNE, MD
Medical Practice at Archer Rd, Gainesville, FL
License number
Florida ME79979
Category
Medical Practice
Type
Pediatric Cardiology
Address
Address
2
1600 SW Archer Rd, Gainesville, FL 32610
PO Box 918025, Orlando, FL 32891
PO Box 918025, Orlando, FL 32891
Phone
(352) 846-1531
(352) 392-4853 (Fax)
(352) 392-4853 (Fax)
Personal information
See more information about BARRY J BYRNE at radaris.comName
Address
Phone
123 NW 23Rd St, Gainesville, FL 32607
7902 45Th Ln, Gainesville, FL 32608
3027 1St Ave, Gainesville, FL 32607
123 NW 23Rd St, Gainesville, FL 32607
Organization information
See more information about BARRY J BYRNE at bizstanding.comBarry J Byrne MD
1600 SW Archer Rd #2, Gainesville, FL 32610
Categories:
Physicians & Surgeons
Phone:
(352) 392-3261 (Phone)
Professional information
Director, Powell Center For Rare Disease Research And Therapy
Position:
Professor at University of Florida, Director, Powell Gene Therapy Center at University of Florida
Location:
Gainesville, Florida Area
Industry:
Research
Work:
University of Florida
since May 1997
-
Professor
University of Florida
since Jan 1997
-
Director, Powell Gene Therapy Center
Johns Hopkins University
Jul 1991 - May 1997
-
Assistant Professor
Education:
Denison University
Bachelor of Science (BS), Chemistry
Bachelor of Science (BS), Chemistry
Skills:
Animal Models, Virology, Genetics, Gene Therapy, In Vivo, Immunohistochemistry, qPCR, Molecular Biology, Immunology, Lifesciences, Drug Development, Biotechnology, Vaccines, Translational Research, Clinical Development, Statistics, Clinical Trials, Clinical Research, Medical Writing, Teaching
Self-Complementary Adeno-Associated Virus Having A Truncated Cmv-Chicken Β-Actin Promoter
US Patent:
8298818, Oct 30, 2012
Filed:
Apr 27, 2007
Appl. No.:
12/298845
Inventors:
Sanford Leon Boye - Gainesville FL, US
William W. Hauswirth - Gainesville FL, US
Barry John Byrne - Gainesville FL, US
William W. Hauswirth - Gainesville FL, US
Barry John Byrne - Gainesville FL, US
Assignee:
University of Florida Research Foundation, Inc. - Gainesville FL
International Classification:
C12N 15/00, C12N 5/00
US Classification:
4353201, 435325
Abstract:
The present inventors concerns vectors carrying a truncated chimeric CMV-chicken β-actin (smCBA) promoter in which the hybrid chicken β-actin/rabbit β-globin intron is greatly shortened, and their use to deliver to an operatively linked polynucleotide to host cells in vitro or in vivo, resulting in expression of the polynucleotide in the host cells. In one embodiment, the vector carrying the smCBA promoter is administered to the eye. In another embodiment, the vector carrying the smCBA promoter is a self-complementary adeno-associated virus (AAV). The AAV vector may be of any serotype (e. g. , type 1, type 2, type 3, type 4, type 5, type 6, type 7, type 8, type 9, type 10). In another embodiment, a self-complementary vector carrying the smCBA promoter is administered to the eye. Another aspect of the invention concerns host cells carrying a vector of the invention. Another aspect of the invention concerns pharmaceutical composition comprising the vectors or host cells of the invention, and a pharmaceutically acceptable carrier.
Barry J Byrne, Gainesville FL
Specialties:
Pediatrician
Address:
1600 Sw Archer Rd, Gainesville, FL 32610
Board certifications:
American Board of Pediatrics Sub-certificate in Pediatric Cardiology (Pediatrics)
Materials And Methods For Gene Therapy
US Patent:
6461606, Oct 8, 2002
Filed:
Apr 23, 1999
Appl. No.:
09/299141
Inventors:
Terence R. Flotte - Gainesville FL
Sihong Song - Gainesville FL
Barry J. Byrne - Gainesville FL
Michael Morgan - Gainesville FL
Sihong Song - Gainesville FL
Barry J. Byrne - Gainesville FL
Michael Morgan - Gainesville FL
Assignee:
University of Florida Research Foundation - Gainesville FL
International Classification:
A01N 6300
US Classification:
424 932, 424 9321, 424 936, 514 44, 4353201, 435325, 435 691, 435455, 536 231, 536 235
Abstract:
The subject invention concerns materials and methods for gene therapy. One aspect of the invention pertains to vectors which can be used to effect genetic therapy in animals or humans having genetic disorders where expression of high levels of a protein of interest are required to treat or correct the disorder. The subject invention also pertains to methods for treating animals or humans in need of gene therapy to treat or correct a genetic disorder. The materials and methods of the invention can be used to provide therapeutically effective levels of a protein that is non-functional, or that is absent or deficient in the animal or human to be treated. In one embodiment, the materials and methods can be used to treat alpha-1-antitrypsin deficiency.
Method Of Preparing Recombinant Adeno-Associated Virus Compositions
US Patent:
6660514, Dec 9, 2003
Filed:
Jul 21, 2000
Appl. No.:
09/621475
Inventors:
Sergei Zolotukhin - Gainesville FL
Barry J. Byrne - Gainesville FL
Nicholas Muzyczka - Gainesville FL
Barry J. Byrne - Gainesville FL
Nicholas Muzyczka - Gainesville FL
Assignee:
University of Florida Research Foundation - Gainesville FL
International Classification:
C12N 702
US Classification:
435239, 435 5, 4352351, 4353201, 435803, 435948, 530412, 530826
Abstract:
Disclosed are methods for the isolation and purification of high-titer recombinant adeno-associated virus (rAAV) compositions. Also disclosed are methods for reducing or eliminating the concentration of helper adenovirus in rAAV samples. Methods are disclosed that provide highly-purified rAAV stocks having titers up to about 10 particles/ml at particle-to-infectivity ratios of less than 100 in processes that are accomplished about 24 hours or less.
Gel-Based Delivery Of Recombinant Adeno-Associated Virus Vectors
US Patent:
2008027, Nov 13, 2008
Filed:
Apr 10, 2008
Appl. No.:
12/100688
Inventors:
Cathryn S. Mah - Gainesville FL, US
Barry J. Byrne - Gainesville FL, US
Barry J. Byrne - Gainesville FL, US
Assignee:
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC - Gainesville FL
International Classification:
A61K 9/14, A61K 35/76, A61P 21/00
US Classification:
424488, 424 932, 424484
Abstract:
Disclosed are water-soluble gel-based compositions for the delivery of recombinant adeno-associated virus (rAAV) vectors that express nucleic acid segments encoding therapeutic constructs including peptides, polypeptides, ribozymes, and catalytic RNA molecules, to selected cells and tissues of vertebrate animals. Also disclosed are gel-based rAAV compositions are useful in the treatment of mammalian, and in particular, human diseases, including for example, cardiac disease or dysfunction, and musculoskeletal disorders and congenital myopathies, including, for example, muscular dystrophy, acid maltase deficiency (Pompe's disease), and the like. In illustrative embodiments, the invention provides rAAV vectors comprised within a biocompatible gel composition for enhanced viral delivery/transfection to mammalian tissues, and in particular to vertebrate muscle tissues such as a human heart or diaphragm tissue.
Adeno-Associated Viral Vectors For The Treatment And Prevention Of Diabetes
US Patent:
2003009, May 22, 2003
Filed:
Jan 10, 2003
Appl. No.:
10/340112
Inventors:
Terence Flotte - Gainesville FL, US
Sihong Song - Gainesville FL, US
Barry Byrne - Gainesville FL, US
Michael Morgan - Gainesville FL, US
Sihong Song - Gainesville FL, US
Barry Byrne - Gainesville FL, US
Michael Morgan - Gainesville FL, US
Assignee:
University of Florida Research Foundation
International Classification:
A61K048/00, C12N015/861
US Classification:
424/093200, 435/456000
Abstract:
The subject invention concerns materials and methods for gene therapy. One aspect of the invention pertains to vectors which can be used to effect genetic therapy in animals or humans having genetic disorders where expression of high levels of a protein of interest are required to treat or correct the disorder. The subject invention also pertains to methods for treating animals or humans in need of gene therapy to treat or correct a genetic disorder. The materials and methods of the invention can be used to provide therapeutically effective levels of a protein that is non-functional, or that is absent or deficient in the animal or human to be treated. In one embodiment, the materials and methods can be used to treat alpha-1-antitrypsin deficiency.
Raav Compositions For Gene Therapy
US Patent:
2003008, May 1, 2003
Filed:
Oct 8, 2002
Appl. No.:
10/267117
Inventors:
Terence Flotte - Gainesville FL, US
Sihong Song - Gainesville FL, US
Barry Byrne - Gainesville FL, US
Michael Morgan - Gainesville FL, US
Sihong Song - Gainesville FL, US
Barry Byrne - Gainesville FL, US
Michael Morgan - Gainesville FL, US
Assignee:
University of Florida Research Foundation
International Classification:
A61K048/00
US Classification:
424/093210, 514/044000
Abstract:
The subject invention concerns materials and methods for gene therapy. One aspect of the invention pertains to vectors which can be used to effect genetic therapy in animals or humans having genetic disorders where expression of high levels of a protein of interest are required to treat or correct the disorder. The subject invention also pertains to methods for treating animals or humans in need of gene therapy to treat or correct a genetic disorder. The materials and methods of the invention can be used to provide therapeutically effective levels of a protein that is non-functional, or that is absent or deficient in the animal or human to be treated. In one embodiment, the materials and methods can be used to treat alpha-1-antitrypsin deficiency.
Method Of Preparing Recombinant Adeno-Associated Virus Compositions
US Patent:
6146874, Nov 14, 2000
Filed:
May 27, 1999
Appl. No.:
9/321897
Inventors:
Sergei Zolotukhin - Gainesville FL
Barry J. Byrne - Gainesville FL
Nicholas Muzyczka - Gainesville FL
Barry J. Byrne - Gainesville FL
Nicholas Muzyczka - Gainesville FL
Assignee:
University of Florida - Gainesville FL
International Classification:
C12N 700, C12N 701, C12N 704, C12N 708, C12N 706
US Classification:
4352351
Abstract:
Disclosed are methods for the isolation and purification of high-titer recombinant adeno-associated virus (rAAV) compositions. Also disclosed are methods for reducing or eliminating the concentration of helper adenovirus in rAAV samples. Methods are disclosed that provide highly-purified rAAV stocks having titers up to about 10. sup. 13 particles/ml at particle-to-infectivity ratios of less than 100 in processes that are accomplished about 24 hours or less.
Production Of Pseudotyped Recombinant Aav Virions
US Patent:
2007001, Jan 18, 2007
Filed:
Jun 5, 2003
Appl. No.:
10/456423
Inventors:
Richard Snyder - Gainesville FL, US
Sergie Zolotukhin - Gainesville FL, US
Yoshihisa Sakai - Gainesville FL, US
Barry Byrne - Gainesville FL, US
Mark Potter - Gainesville FL, US
Irine Zolotukhin - Gainesville FL, US
Scott Loiler - Gainesville FL, US
Vince Chiodo - Gainesville FL, US
Nicholas Muzyczka - Gainesville FL, US
William Hauswirth - Gainesville FL, US
Terence Flotte - Alachua FL, US
Corinna Burger - Gainesville FL, US
Edgardo Rodriguez - Gainesville FL, US
Sergie Zolotukhin - Gainesville FL, US
Yoshihisa Sakai - Gainesville FL, US
Barry Byrne - Gainesville FL, US
Mark Potter - Gainesville FL, US
Irine Zolotukhin - Gainesville FL, US
Scott Loiler - Gainesville FL, US
Vince Chiodo - Gainesville FL, US
Nicholas Muzyczka - Gainesville FL, US
William Hauswirth - Gainesville FL, US
Terence Flotte - Alachua FL, US
Corinna Burger - Gainesville FL, US
Edgardo Rodriguez - Gainesville FL, US
International Classification:
C12P 21/06, C12N 7/00, C12N 15/861, C12N 5/06
US Classification:
435069100, 435456000, 435235100, 435325000, 977802000
Abstract:
Vectors that encode Adeno-Associated Virus (AAV) Rep and Cap proteins of different serotypes and Adenovirus transcription products that provide helper functions were used to produce pseudotyped recombinant AAV (rAAV) virions. Purification methods generated pseudotyped rAAV virion stocks that were 99% pure with titers of 1×10−1×10vector genomes/ml.